2024-11-20 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**1. Performance Relative to S&P 500 (VOO):**

AbbVie Inc. (ABBV) is a biopharmaceutical company researching, developing, and selling medicines globally.  The cumulative return of ABBV is 146.82%, while the S&P 500 (VOO) shows a cumulative return of 124.78%.  This represents a difference of 22.04%, placing ABBV's performance at the 41.11th percentile relative to its historical performance against the S&P 500 (based on a range of max 98.19% and min -31.11%).

**Alpha/Beta Analysis:**  The provided data shows that ABBV has generally outperformed the market (Beta >1) in the past, though this has decreased recently (Beta <1 since 2020). Alpha is highly variable.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 63.2% | 22.2% | 24.8% | 1.0 | 170.9 |
| 2016-2018  | 79.0% | 27.3% | 46.7% | 1.0 | 162.9 |
| 2017-2019  | 61.4% | 30.2% | 9.7% | 1.1 | 156.5 |
| 2018-2020  | 26.1% | 33.4% | -21.2% | 0.8 | 189.3 |
| 2019-2021  | 77.3% | 33.4% | -22.7% | 0.7 | 239.3 |
| 2020-2022  | 107.4% | 33.4% | 83.8% | 0.6 | 285.6 |
| 2021-2023  | 66.5% | 20.4% | 31.6% | 0.4 | 273.9 |
| 2022-2024  | 37.6% | 20.4% | 9.1% | 0.3 | 291.6 |


**2. Recent Price Movement:**

* Closing Price: $166.28 (Last Market: $165.48)
* 5-Day Moving Average: $168.47
* 20-Day Moving Average: $188.12
* 60-Day Moving Average: $191.26

The stock is trading below its short-term and long-term moving averages, suggesting a downward trend.

**3. Technical Indicators:**

* RSI: 29.68 (Suggests oversold conditions)
* PPO: -1.99 (Indicates bearish momentum)
* Recent (20-day) Relative Divergence Change: -24.96% (Indicates a short-term downward trend)
* Expected Return (2+ years): 24.09% (Superior to S&P 500)

Given the RSI and PPO readings and the negative relative divergence, a bearish outlook is indicated. However, the expected return suggests long-term potential. The fact that the last market price ($165.48) is close to the closing price does not indicate a significant rapid increase or decrease.


**4. Recent Financial Performance:**

| Date       | EPS     | Expected EPS |
|------------|---------|--------------|
| 2024-10-30 | 3       | 2.92         |
| 2024-07-25 | 2.65    | 2.57         |
| 2024-04-26 | 2.31    | 2.26         |
| 2024-02-02 | 2.79    | 2.76         |
| 2023-10-27 | 2.95    | 2.86         |

AbbVie has consistently exceeded EPS expectations in recent quarters, demonstrating strong profitability. The most recent quarter (Oct 30, 2024) showed a slight beat over the estimates.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-09-30  | $14.46B    | 70.87%        |
| 2024-06-30  | $14.46B    | 70.94%        |
| 2024-03-31  | $12.31B    | 66.74%        |
| 2023-12-31  | $14.30B    | 60.11%        |
| 2023-09-30  | $13.93B    | 53.44%        |

Revenue has been relatively stable, while profit margins have shown some fluctuation but overall a positive trend.

**2) Capital and Profitability:**

| Quarter     | Equity      | ROE           |
|-------------|-------------|---------------|
| 2024-09-30  | $6.03B     | 25.88%        |
| 2024-06-30  | $6.78B     | 20.21%        |
| 2024-03-31  | $8.01B     | 17.10%        |
| 2023-12-31  | $10.36B    | 7.93%         |
| 2023-09-30  | $12.09B    | 14.70%        |

Equity and ROE show fluctuations, potentially influenced by share buybacks and other financial activities.

**6. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews and Finbold.  Please provide recent news articles for a complete analysis.)*  This section would include any recent earnings announcements, analyst ratings changes, and significant market events affecting ABBV.

**7. Overall Analysis:**

AbbVie shows strong profitability and has historically outperformed the S&P 500. Recent performance, however, is showing signs of weakening (lower beta, below moving averages). Technical indicators suggest an oversold condition, but bearish momentum.  The company's consistent EPS beats are positive, but the long-term outlook is contingent on sustained revenue growth and maintaining high profit margins.  Further analysis is needed considering recent news and analyst opinions to determine the best course of action.

**8. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  Conduct thorough research and consult with a financial advisor before making any investment decisions.  The analysis is based on limited data and may not reflect future performance.
